News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • DexCom shares jumped after Q2 beat, margin improvements, raised guidance and a large share-repurchase program.
  • BioAge stock plunged about 60% after Novo Nordisk's Phase 3 ZEUS trial failed to reduce major cardiovascular events.
  • Karyopharm shares collapsed after its Phase 3 endometrial cancer trial missed the primary endpoint, prompting program cutbacks and analyst downgrades.
  • Citi reports buy-the-dip behavior into the Kospi as foreign and pension flows turn positive, supporting a 10,000 index target.
  • GAO says the $21 billion Boeing-managed B-52 modernization program is over budget, behind schedule and facing performance risks.
  • Greenland Mines says international interest surged after U.S. political remarks, advancing precious metals and rare-earth projects tied to Western supply chains.

Latest Articles

LiqTech International Announces First Quarter 2026 Financial Results

LiqTech International Announces First Quarter 2026 Financial Results

LiqTech International announced its Q1 2026 financial results showing a slight decline in revenue to $4.1 million compared to the prior year, and a net loss widening to $2.7 million. The company highlighted growth in commercial pool and marine water treatment markets along with a positive outlook expecting 39% to 64% revenue growth for full-year 20…

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

Moleculin Biotech announced that the MIRACLE trial evaluating Annamycin plus cytarabine in relapsed/refractory acute myeloid leukemia (AML) is on track for first interim unblinding of data by June 30, 2026. Preliminary blinded data from 45 patients show a complete remission rate (~30%) approximately double historical rates for cytarabine alone. Rec…

Swarmer Reports First Quarter Financial Results

Swarmer Reports First Quarter Financial Results

Swarmer, Inc, a drone autonomy software company, reported its first quarter 2026 financial results following its successful Nasdaq IPO. The company raised $17.3 million and announced key contract wins and expansion into Japan. Despite these positive developments, revenue declined significantly due to the conclusion of a major customer engagement, w…

Diginex Appoints Archana Kotecha as Chief Impact Officer to Advance Human Rights and Scale Supply Chain Solutions in a $9.6B Market

Diginex Appoints Archana Kotecha as Chief Impact Officer to Advance Human Rights and Scale Supply Chain Solutions in a $9.6B Market

Diginex Limited appoints Archana Kotecha, founder of The Remedy Project, as Chief Impact Officer to enhance its human rights and supply chain due diligence capabilities amid a rapidly growing $9.6 billion market. The move supports Diginex's strategy to scale sustainable regulatory compliance solutions using advanced technologies and expands its glo…

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

ARS Pharmaceuticals has announced the appointment of Donn Casale as its new President, effective June 1, 2026. Casale brings 25 years of biopharmaceutical commercial leadership experience, having previously scaled successful healthcare products. His role will focus on overseeing global commercial operations and driving growth, particularly advancin…

NOVAGOLD Releases 2025 Sustainability Report

NOVAGOLD Releases 2025 Sustainability Report

NOVAGOLD Resources Inc. released its 2025 Sustainability Report detailing its environmental, social, and governance (ESG) performance aligned with global standards such as TCFD and TNFD. The report emphasizes NOVAGOLD's responsible advancement of the Donlin Gold project, strong community engagement, and commitment to sustainable mining development …

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion Therapeutics announced the presentation of new analyses at the European Atherosclerosis Society Congress 2026. The data highlights the efficacy of bempedoic acid in lowering LDL cholesterol in children with heterozygous familial hypercholesterolemia as well as factors enhancing LDL-C reduction in adults. These findings support advancing be…

Gildan Announces the Publication of its 2025 Sustainability Report Highlighting Continued Progress Towards Key Social and Environmental Targets¹

Gildan Announces the Publication of its 2025 Sustainability Report Highlighting Continued Progress Towards Key Social and Environmental Targets¹

Gildan Activewear Inc. released its 22nd Sustainability Report showcasing continued achievements under its Next Generation Sustainability strategy. In 2025, the company met its sustainable cotton sourcing goals, reduced water intensity by approximately 25%, increased recycled fiber usage, and enhanced health and safety standards with ISO certificat…

Axon Shares Slip After Investor Highlights AI Potential at Sohn Conference

Axon Shares Slip After Investor Highlights AI Potential at Sohn Conference

Axon Enterprise shares edged lower after investor Rahul Kishore presented the company at the Sohn investment conference at Lincoln Center. Kishore, founder of Epicenter Capital and former Coatue executive, framed Axon's growth prospects around artificial intelligence. The presentation included an AI-generated introduction from an assistant named Ev…

UBS Reaffirms Top Picks in European Energy After Strong Q1 Performance

UBS Reaffirms Top Picks in European Energy After Strong Q1 Performance

UBS has reiterated a bullish stance on select large European energy companies following a solid first-quarter earnings period. The broker points to robust oil trading, resilient refining margins and enhanced shareholder returns as drivers behind a sector-wide 6% earnings beat, and names TotalEnergies and Eni as its preferred picks while upgrading B…

German Court Finds Mondelez Misled Consumers Over Milka Bar Size Reduction

German Court Finds Mondelez Misled Consumers Over Milka Bar Size Reduction

On May 13 a German court determined that Mondelez misled consumers by reducing the net weight of some Milka chocolate bars from 100 grams to 90 grams while leaving the packaging largely unchanged. The ruling, brought forward by a consumer protection agency, requires a clear notice on packaging for at least four months after the change to prevent co…

Carrefour Shares Rise After French Appeals Court Limits Franchisees' Claims

Carrefour Shares Rise After French Appeals Court Limits Franchisees' Claims

Carrefour shares climbed about 1% after the Paris Court of Appeal found that the Rennes Commercial Court does not have jurisdiction over claims lodged by the Carrefour Franchisees Association (AFC). The judgment overturns the earlier decision, affirms the validity of arbitration clauses in Carrefour's franchise contracts, and requires any future cl…

HSBC’s Max Kettner Sticks With Maximum Bullish Bet on Risk Assets

HSBC’s Max Kettner Sticks With Maximum Bullish Bet on Risk Assets

HSBC chief multi-asset strategist Max Kettner retains the bank’s most bullish allocation to global equities, arguing that positioning is not signalling a sell and that systematic investors have capacity to add. The bank stays overweight equities, emerging market local debt and high-yield credit, while remaining most underweight U.S. Treasuries vers…

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Dyne Therapeutics, a clinical-stage biopharmaceutical company focused on genetically driven neuromuscular diseases, announced its management team's participation in three major 2026 investor healthcare conferences with live fireside chats and meetings. The company is advancing clinical and preclinical programs for diseases including Duchenne muscul…